Abstract
Both decrease in GABAergic inhibition and increase in glutamatergic excitation are thought to be critically involved in the cellular mechanisms underlying the initiation and spread of epileptic seizures and the processes that lead to epileptogenesis and, as a consequence, chronic epilepsy.3,7,8,17,18,31,34 The kindling model of tem oral lobe epilepsy has been particularly helpful in elucidating the important roles of inhibitory and excitatory synaptic function in the development and spread of epileptic activity.34 Based on findings in the kindling and other models of epilepsy, increasing GABAergic transmission and decreasing glutamatergic transmission have been proposed as promising antiepileptic strategies with potential advantages compared with current therapies.17,31 Various drugs which selectively potentiate GABAergic transmission have been developed over the last three to four decades and some of them, e.g. vigabatrin, have recently been marketed for treatment of epilepsy.29 In contrast to the long history of the “GABA hypothesis of epilepsy” and GABAergic drugs developed because of this hypothesis,17 it was not until the development in the early 1980s of subtype-selective excitatory amino acid (EAA) receptor agonists and antagonists that the role of EAA receptor systems in the generation of epileptic activity was fully recognized.34 This initiated an enormous interest in the potential therapeutic use of EAA receptor antagonists in epilepsy and other brain disorders for which an involvement of glutamatergic transmission has been suggested. However, it took several years before systemically active compounds (i.e., compounds which pass the blood-brain-barrier after systemic administration) became available. Furthermore, the vast majority of studies on anticonvulsant effects of such compounds was done in experimental models of acute seizures, while until recently no systematic drug evaluation in chronic models of epilepsy such as kindling was reported.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bacia, T., Szpiro-Zurkowska, A., Bidzinski, J. and Czarkwiani, L. Use of ketamine for activation of EEG and electrocorticographic records in patients with epilepsy, Epilepsia, 30 (1989) 642
Bettler, B. and Mulle, C. Neurotransmitter receptors II: AMPA and kainate receptors, Neuropharmacologv, 34 (1995) 123–139.
Bradford, H.F. Glutamate, GABA and epilepsy, Progr. Neurobiol. 47 (1995)
Carter, A.J. Glycine antagonists: regulation of the NMDA receptor-channel complex by the strychnine-insensitive glycine site, Drugs Future, 17 (1992) 595–613.
Carter, A.J. Antagonists of the NMDA receptor-channel complex and motor coordination, Life Sci. 57 (1995) 917–929.
Cotman, C.W., Kahle, J.S., Miller, S.E., Ulas, J. and Bridges, R.J. Excitatory amino acid neurotransmission. In F.E. Bloom and D.J. Kupfer (Eds.) Psychopharmacology. The fourth generation of progress, Raven Press, New York, 1995, pp. 75–85.
Dichter, M.A. Cellular mechanisms of epilepsy and potential new treatment strategies, Epilepsia, 30 (Suppl. 1) (1989) S12
Dingledine, R., McBain, C.J. and McNamara, J.O. Excitatory amino acid receptors in epilepsy, Trends Pharmacol. Sci. 11 (1990) 334–338.
Dziki, M., Hönack, D. and Löscher, W. Kindled rats are more sensitive than non-kindled rats to the behavioural effects of combined treatment with MK-801 and valproate, Eue J. Pharmacol. 222 (1992) 273–278.
Garcia, Y., Ibarra, C. and Jaffe, E.H. NMDA and non-NMDA receptor-mediated release of [H-3]GABA from granule cell dendrites of rat olfactory bulb, J. Neurochem, 64 (1995) 662–669.
Hönack, D. and Löscher, W. Sex differences in NMDA receptor mediated responses in rats, Brain Res. 620 (1993) 167–170.
Johansen, T.H., Drejer, J., Watjen, F. and Nielsen, E.O. A novel non-NMDA receptor antagonist shows selective displacement of low-affinity [3H]kainate binding, Eur. J. Pharmacol. 246 (1993) 195
Jorgensen, M., Tygesen, C.K: and Andersen, P.H. Ionotropic glutamate receptors-focus on non-NMDA receptors, Pharmacol. Toxicol. 76 (1995) 312–319.
Kemp, J.A. and Leeson, P.D. The glycine site of the NMDA receptor-five years on, Trends Pharmacol. Sci. 14 (1994) 20–25.
Koek, W. and Colpaert, F.C. Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: relationship with phencyclidine-like behavioral effects, J. Pharmacol. Exp. Ther. 252 (1990) 349–357.
Lapin, I.P., Prakhie, I.B. and Kiseleva, I.P. Excitatory effects of kynurenine and its metabolites, amino acids and convulsants administered into brain ventricles: differences between rats and mice, J. Neural Trans. 54 (1982) 229–238.
Löscher, W. GABA and the epilepsies. Experimental and clinical considerations. In N.G. Bowery and G. Nisticò (Eds.) GABA. Basic research and clinical applications, Pythagora Press, Rome, 1989, pp. 260–300.
Löscher, W. Basic aspects of epilepsy, Curr. Opin. Neurol. Neurosurg. 6 (1993) 223–232.
Löscher, W. and Hönack, D. High doses of memantine (1-amino-3,5-dimethyladamantane) induce seizures in kindled but not in non-kindled rats, Naunyn-Schmiedebergs Arch. Pharmacol. 341 (1990) 476–481.
Löscher, W. and Hönack, D. Responses to NMDA receptor antagonists altered by epileptogenesis, Trends Pharmacol. Sci. 12 (1991) 52
Löscher, W. and Hönack, D. The novel competitive N-methyl-D-aspartate (NMDA) antagonist CGP 37849 preferentially induces phencyclidine-like behavioral effects in kindled rats: attenuation by manipulation of dopamine, alpha-1 and serotoninl1A receptors, J. Pharmacol. Exp. Ther. 257 (1991) 1146–1153.
Löscher, W. and Hönack, D. Anticonvulsant and behavioral effects of two novel competitive N-methyl-Daspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-80I and carbamazepine, J. Pharmacol. Exp. Ther. 256 (1991) 432–440.
Löscher, W. and Hönack, D. Differences in anticonvulsant potency and adverse effects between dextromethorphan and dextrorphan in amygdala-kindled and non-kindled rats, Eur J. Pharmacol. 238 (1993) 191–200.
Löscher, W. and Hönack, D. Effects of the competitive NMDA receptor antagonist, CGP 37849, on anti-convulsant activity and adverse effects of valproate in amygdala-kindled rats, Eur. J. Pharmacol. 234 (1993) 237–245.
Löscher, W. and Hönack, D. Over-additive anticonvulsant effect of memantine and NBQX in kindled rats, Eur J. Pharmacol. 259 (1994) R3–R5.
Löscher, W., Nolting, B. and Hönack, D. Evaluation of CPP, a selective NMDA antagonist, in various rodent models of epilepsy. Comparison with other NMDA antagonists, and with diazepam and phenobarbital, Eur. J Pharmacol. 152 (1988) 9–17.
Löscher, W., Rundfeldt, C. and Hönack, D. Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy, Eur. J. Neurosci. 5 (1993) 1545–1550.
Löscher, W. and Schmidt, D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations, Epilepsy Res. 2 (1988) 145–181.
Löscher, W. and Schmidt, D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. 17 (1994) 95–134.
Löscher, W., Wlaz, P., Rundfeldt, C., Baran, H. and Hönack, D. Anticonvulsant effects of the glycine/NMDA receptor ligands D-cycloserine and D-serine but not R-(+)-HA-966 in amygdala-kindled rats, Brit. J. Pharmacol. 112 (1994) 97–106.
Meldrum, B.S. Excitatory amino acids in epilepsy and potential novel therapies, Epilepsy Res. 12 (1992) 189–196.
Perouansky, M. and Grantyn, R. Is GABA release modulated by presynaptic excitatory amino acid receptors? Neurosci. Lett. 113 (1990) 292–297.
Rogawski, M.A. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines, Trends Pharmacol. Sci. 14 (1993) 325–331.
Rogawski, M.A. Excitatory amino acids and seizures. In T.W. Stone (Ed.) CNS neurotransmitters and neuromodulators: glutamate, CRC Press, Boca Raton, 1995, pp. 219–237.
Rundfeldt, C., Hönack, D. and Löscher, W. Phenytoin potently increases the threshold for focal seizures in amygdala-kindled rats, Neuropharmacology, 29 (1990) 845–851.
Stone, T.W. Subtypes of NMDA receptors, Gen. Pharmacol. (1993) 825–832.
Sveinsbjornsdottir, S., Sander, J.W.A.S., Upton, D., Thompson, P.J., Patsalos, P.N., Hirt, D., Emre, M., Lowe, D. and Duncan, J.S. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy, Epilepsy Res. 16 (1993) 165–174.
Verdoorn, T.A., Johansen, T.H., Drejer, J. and Nielsen, E.O. Selective block of recombinant glur6 receptors by NS-102, a novel non-NMDA receptor antagonist, Eur. J. Pharmacol. 269 (1994) 43–49.
Wlaz, R, Ebert, U. and Löscher, W. Low doses of the glycine/NMDA receptor antagonist R-(+)-HA-966 but not D-cycloserine induce paroxysmal activity in limbic brain regions of kindled rats, Eur. J. Neurosci. 6 (1994) 1710–1719.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Löscher, W. (1998). Pharmacology of Glutamate Receptor Antagonists in the Kindling Model. In: Corcoran, M.E., Moshé, S.L. (eds) Kindling 5. Advances in Behavioral Biology, vol 48. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5375-5_31
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5375-5_31
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7453-4
Online ISBN: 978-1-4615-5375-5
eBook Packages: Springer Book Archive